Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy?
For most patients with head and neck cancer, locoregional disease recurrence carries an extremely poor prognosis and has severe adverse effects on quality of life. Only a few patients are suitable for salvage surgery and, even in selected cases, the success rate is low. Most patients are managed by supportive palliative care, or with palliative chemotherapy. In the UK, re-irradiation is rarely used because of concerns about treatment-related toxicity and lack of efficacy. Despite this, a significant body of evidence suggests that re-irradiation may have a higher probability of achieving local control than other treatments. In this review, we discuss the use of re-irradiation in patients with locally recurrent head and neck cancer, and present the pertinent data.
Creak
A L
AL
The Royal Marsden Hospital, London, UK.
Harrington
K
K
Nutting
C
C
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010166:Palliative Care; D011878:Radiotherapy / Q000379:methods*; D016879:Salvage Therapy
D000970:Antineoplastic Agents